All In Biotech

Drug Trial Radar · NCT06681181

A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants

A Phase 1, Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

48

Actual

Start

Nov 18, 2024

Primary completion

Apr 23, 2026

Study completion Mar 11, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

"GSK4528287 is a drug being developed to treat like inflammatory bowel diseases like Crohns disease and ulcerative colitis. This study is the first time that GSK4528287 will be given to humans. The study will test single doses of GSK4528287 to check for side effects, measure blood levels, and understand how it works in the body. The study will start with a small dose, and the dose will be increased for each new group of participants."

Conditions

  • Colitis, Ulcerative

Interventions

  • GSK4528287Drug

    GSK4528287 will be administered.

  • PlaceboDrug

    Placebo will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AE)Time frame: Up to Day 351 (End of follow up period)
  2. Number of Participants with Serious Adverse Events (SAE)Time frame: Up to Day 351 (End of follow up period)
  3. Number of Participants with Clinically Significant Changes in Laboratory ValuesTime frame: Up to Day 351 (End of follow up period)
  4. Number of Participants with Clinically Significant Changes in Vital SignsTime frame: Up to Day 351 (End of follow up period)
  5. Number of Participants with Clinically Significant Changes in TelemetryTime frame: On Day 1
  6. Number of Participants with Clinically Significant Changes in 12 lead Electrocardiogram (ECG)Time frame: Up to Day 351 (End of follow up period)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Cambridge, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.